Cindy Chmielewski @MyelomaTeacher
@myelomateacher.bsky.social
Wife, mother, “retired” educator and animal lover. #Myeloma patient Dx 2008 - Myeloma research advocate #mmsm
Pinned
Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma
Its always nice to hear from the basic researchers. Their successes in the lab eventually transfer to patient care. Thanks! youtu.be/VHE5-RQJnf8?...
#MMsm #ASH24 #HealthTree #myeloma
#MMsm #ASH24 #HealthTree #myeloma
Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi & Erin Meermeier | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 21, 2024 at 6:57 PM
Its always nice to hear from the basic researchers. Their successes in the lab eventually transfer to patient care. Thanks! youtu.be/VHE5-RQJnf8?...
#MMsm #ASH24 #HealthTree #myeloma
#MMsm #ASH24 #HealthTree #myeloma
Today’s ASH highlight video is on Cevostamab-a fixed duration bispecific antibody that targets FCRH5 youtu.be/kHNBPB1S7QY?... #MMsm #ASH24 #HealthTree #myeloma
Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 18, 2024 at 5:15 PM
Today’s ASH highlight video is on Cevostamab-a fixed duration bispecific antibody that targets FCRH5 youtu.be/kHNBPB1S7QY?... #MMsm #ASH24 #HealthTree #myeloma
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 youtu.be/oZfpQWdgiSc?...
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 16, 2024 at 11:00 PM
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 youtu.be/oZfpQWdgiSc?...
Another Myeloma maintenance study- Auriga Study Subgroup Update - youtu.be/xKaOtop1fik?... #MMsm #ASH24 #HealthTree #myeloma
Daratumumab + Lenalidomide Vs Lenalidomide Alone As Maintenance Therapy | Laahn Foster, MD | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 16, 2024 at 10:58 PM
Another Myeloma maintenance study- Auriga Study Subgroup Update - youtu.be/xKaOtop1fik?... #MMsm #ASH24 #HealthTree #myeloma
Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma
December 15, 2024 at 8:49 PM
Happy to see patients as influencers at major medical meetings. It is so important to include all perspectives in the conversations. #MMsm #ASH24 #HealthTree #myeloma
To treat or not to treat (HR-SMM) - Listen to @thanosdimop talk about the results of the Aquila trial #MMsm #ASH24 #HealthTree #myeloma youtu.be/C7f-cTLBBfo
Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 15, 2024 at 3:29 PM
To treat or not to treat (HR-SMM) - Listen to @thanosdimop talk about the results of the Aquila trial #MMsm #ASH24 #HealthTree #myeloma youtu.be/C7f-cTLBBfo
Reaching MRD negativity is the goal of #myeloma treatment. The CoMMander trial used Iberdomide to achieve this in Post-ASCT patients who had residual disease after 100 days. @healthtreeorg.bsky.social #MMSM #ASH24 m.youtube.com/watch?v=MiWM...
Iberdomide Combos Post-ASCT in Myeloma: Eliminating Residual Disease (COMMANDER) |Dr. Costa | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
m.youtube.com
December 15, 2024 at 2:51 AM
Reaching MRD negativity is the goal of #myeloma treatment. The CoMMander trial used Iberdomide to achieve this in Post-ASCT patients who had residual disease after 100 days. @healthtreeorg.bsky.social #MMSM #ASH24 m.youtube.com/watch?v=MiWM...
Reposted by Cindy Chmielewski @MyelomaTeacher
New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session
December 9, 2024 at 12:30 AM
New-to-blue but feared by myeloma and well-known to the myeloma world: @drmhb.bsky.social moderating #ASH24 myeloma treatment session
Tri-specific Antibody #SAR442257 in RRMM and Non- Hodgkin Lymphoma
#MMsm #ASH24 #HealthTree #myeloma
youtu.be/7NzP-E9WnRo
#MMsm #ASH24 #HealthTree #myeloma
youtu.be/7NzP-E9WnRo
Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fredrik Schjesvold | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 14, 2024 at 3:47 AM
Tri-specific Antibody #SAR442257 in RRMM and Non- Hodgkin Lymphoma
#MMsm #ASH24 #HealthTree #myeloma
youtu.be/7NzP-E9WnRo
#MMsm #ASH24 #HealthTree #myeloma
youtu.be/7NzP-E9WnRo
There is a new CAR on the block and it’s performing exceptionally well. This is one of the many videos that is posted on the @HealthTree for Multiple Myeloma YouTube channel where our ASH coverage will be featured . #MMsm #ASH24 #HealthTree #myeloma
youtu.be/sx89o8X7vvU
youtu.be/sx89o8X7vvU
Phase 1 Study of Antio-cel an Anti-BCMA CAR-T for RRMM | Michael Bishop | #ASH24
YouTube video by HealthTree Foundation for Multiple Myeloma
youtu.be
December 14, 2024 at 3:37 AM
There is a new CAR on the block and it’s performing exceptionally well. This is one of the many videos that is posted on the @HealthTree for Multiple Myeloma YouTube channel where our ASH coverage will be featured . #MMsm #ASH24 #HealthTree #myeloma
youtu.be/sx89o8X7vvU
youtu.be/sx89o8X7vvU
Reposted by Cindy Chmielewski @MyelomaTeacher
Excited that the results of the phase I/II trial of modakafusp alfa in patients with relapsed/refractory multiple myeloma are now published in @bloodjournal.bsky.social. This agent has a novel mechanism of action and has single-agent activity.
#mmsm
#mmsm
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma - PubMed
Interferon-alpha has activity against multiple myeloma. Modakafusp alfa is an immunocytokine comprising two attenuated interferon-alpha2b molecules and an anti-CD38 IgG4 antibody, targeting delivery o...
pubmed.ncbi.nlm.nih.gov
December 11, 2024 at 3:49 PM
Excited that the results of the phase I/II trial of modakafusp alfa in patients with relapsed/refractory multiple myeloma are now published in @bloodjournal.bsky.social. This agent has a novel mechanism of action and has single-agent activity.
#mmsm
#mmsm
Thanks for including a patient advocate on this important research project! #MMsm #ASH24 #HealthTree #myeloma
It was wonderful to get together in-person with our multi-site team working on the LimiTec trial of limited-duration teclistamab therapy for rel/ref #myeloma at #ASH24! Thanks to Leukemia & Lymphoma Society for supporting our trial! clinicaltrials.gov/study/NCT059... @myelomateacher.bsky.social
December 14, 2024 at 3:22 AM
Thanks for including a patient advocate on this important research project! #MMsm #ASH24 #HealthTree #myeloma
Reposted by Cindy Chmielewski @MyelomaTeacher
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd - Update: 12/4/24 - cc @grpetersen1 - @bdermanmd @bhemato @DrOlaLandgren @End_myeloma @HadidiSamer @jmikhaelmd @ManniMD1 @MeeraMohanMD @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @Taxkourel @VincentRK
December 5, 2024 at 12:50 AM
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd - Update: 12/4/24 - cc @grpetersen1 - @bdermanmd @bhemato @DrOlaLandgren @End_myeloma @HadidiSamer @jmikhaelmd @ManniMD1 @MeeraMohanMD @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @Taxkourel @VincentRK
Reposted by Cindy Chmielewski @MyelomaTeacher
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 26, 2024 v2 - cc @grpetersen1 - @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani et al.
November 27, 2024 at 4:45 AM
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 26, 2024 v2 - cc @grpetersen1 - @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani et al.
Reposted by Cindy Chmielewski @MyelomaTeacher
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 20, 2024 - cc @grpetersen1 - @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD
@szusmani et al.
@szusmani et al.
November 20, 2024 at 6:19 PM
Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 20, 2024 - cc @grpetersen1 - @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD
@szusmani et al.
@szusmani et al.
Reposted by Cindy Chmielewski @MyelomaTeacher
November 17, 2024 at 3:08 PM